Can special lenses or drops stop Kids' eyesight from worsening?
NCT ID NCT07095894
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests two treatments to slow the progression of myopia (nearsightedness) in children aged 5 to 12. One treatment is a daily eye drop with a low dose of atropine, and the other is a special type of eyeglass lens. The trial will include 348 children and follow them for 2 years to see if these treatments reduce eye growth and prescription changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOPIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Boston Children's Hospital Waltham
RECRUITINGBoston, Massachusetts, 02453, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Casey Eye Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke University Eye Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact Email: •••••@•••••
-
Illinois College of Optometry
RECRUITINGChicago, Illinois, 60616, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Marshall B. Ketchum University
RECRUITINGFullerton, California, 92831, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University College of Optometry
RECRUITINGColumbus, Ohio, 43210-1280, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pediatric Ophthalmology Associates, Inc.
RECRUITINGColumbus, Ohio, 43205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University
RECRUITINGPalo Alto, California, 94303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UAB Pediatric Eye Care; Birmingham Health Care
RECRUITINGBirmingham, Alabama, 35294, United States
-
University of Houston - College of Optometry
RECRUITINGHouston, Texas, 77204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vanderbilt University Medical Center - Vanderbilt Eye Institute
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
0.05% atropine eyedrops and spectacle lenses with highly aspherical lenslets (HAL)
What this could lead to
If successful, this could provide effective, non-surgical options to slow worsening nearsightedness in children, reducing the need for stronger prescriptions and lowering long-term eye health risks.
What could go wrong
This is a Phase 3 trial, but previous results in non-Asian children have been inconsistent. The treatments may not work as well in this broader population, and atropine drops can cause side effects like light sensitivity or blurred near vision.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.